The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,703.00
Bid: 4,702.00
Ask: 4,706.00
Change: 54.00 (1.16%)
Spread: 4.00 (0.085%)
Open: 4,687.00
High: 4,716.00
Low: 4,632.00
Prev. Close: 4,649.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

22 Sep 2023 07:00

RNS Number : 2836N
Croda International PLC
22 September 2023
 

22 September 2023

 

 

Croda International Plc

 

Appointment of Chair Designate

 

Croda International Plc ("Croda" or "the Company") today announces that it has appointed Danuta Gray as a Non-Executive Director and Chair Designate. Danuta will join the Board with effect from 1 February 2024 and will succeed Dame Anita Frew (DBE) as Chair at the conclusion of the Company's AGM on 24 April 2024. Anita will then retire from the Board after nine years as Croda's Chair.

 

Danuta has held Board positions with both FTSE 100 and FTSE 250 companies across a range of sectors for the past nineteen years. She is currently Chair of Direct Line Insurance Group Plc and a Non-Executive Director and Chair of the Remuneration Committee at Burberry Group plc. She is also a member of the Employ Autism Development Board.

 

Danuta has extensive Non-Executive listed company Board experience having previously been Chair of St Modwen Property plc and also having served on the Boards of: Aldermore Bank plc, Old Mutual plc, Page Group plc, Paddy Power plc and Aer Lingus plc as well as a Non-Executive Member of the Defence Board of the UK Ministry of Defence.

 

On joining the Board, Danuta will be appointed to the Nomination Committee and will succeed Anita Frew as Chair of the Nomination Committee in April 2024.

 

Jacqui Ferguson, Senior Independent Director said:

 

"I am delighted that the comprehensive search process for our next Chair has resulted in the appointment of Danuta. Danuta is a highly experienced Non-Executive Director and Chair with a deep understanding of growing consumer focused and high technology businesses in international markets. She has served on the Boards of a variety of listed companies and her depth of Boardroom experience and strong understanding of UK governance will be of enormous benefit to Croda.

 

On behalf of the Board and everyone at Croda, I would like to thank Anita for her outstanding commitment to Croda since 2014 and her leadership of the Board and stewardship during what has been a period of significant growth and strong performance".

 

Danuta Gray said:

 

"I feel tremendous affinity with Croda given the Group's strong customer focus, market-leading innovation and passion for using smart science to improve lives. With its talented employees, positive culture and refocused portfolio, Croda has an exciting future and I look forward to working with the Croda team to deliver on opportunities that are ahead."

 

Dame Anita Frew, Chair said:

 

"It has been my great privilege to work with Croda and to serve as Chair of the Board since 2014 and I am delighted that I will in due course be handing over the reins to Danuta who will help steer Croda through this next phase."

 

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAZZGZLNMNGFZM
Date   Source Headline
25th Apr 202410:01 amRNSResult of AGM
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.